Our findings indicate that the novel lncRNA BC032913 could serve as a novel prognostic marker and effective therapeutic target for CRC. A total of 115 CRC patients were included in the survival analysis, which was conducted using the Kaplan-Meier method. A log-rank test was employed to compare differences between survival curves. Although TIMP3 plays a significant role in cancers, limited data are available regarding the mechanism of TIMP3 dysregulation. It has been documented that aberrant methylation of TIMP-3 occurs in primary cancers of the colon, lung, breast, kidney, and brain.